Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1067/mtc.2003.49 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Symptoms, coronary artery disease and percutaneous coronary intervention: connecting the dots.
Curr Opin Cardiol
August 2025
National Heart and Lung Institute, Imperial College London.
Purpose Of Review: Symptom relief is now recognized as the primary remit of percutaneous coronary intervention (PCI) in patients with stable coronary artery disease. The relationship between the nature of angina symptoms and the likelihood of successful symptom relief from PCI had not been systematically studied until recently.
Recent Findings: The ORBITA-2 symptom-stratified analysis found that while the severity and nature of symptoms were poorly associated with the severity of coronary disease, the nature of the symptoms powerfully predicted the efficacy of PCI in relieving angina.
[Nanosecond retinal laser therapy: three years of practical experience].
Vestn Oftalmol
September 2025
Korolev Samara National Research University, Samara, Russia.
Objective: This study evaluated the outcomes of a 36-month follow-up after treatment with the ELLEX 2RT nanosecond laser.
Material And Methods: The study included 72 patients divided into two groups. Group 1 received 2RT nanosecond laser therapy, while group 2 did not undergo laser treatment.
Opioid agonist therapy for opioid use disorder in primary versus specialty care.
Cochrane Database Syst Rev
September 2025
Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada.
Background: Opioid use disorder (OUD) is commonly treated in specialized care settings with long-acting opioid agonists, also known as opioid agonist therapy, or OAT. Despite the rise in opioid use globally and evidence for a 50% reduction in mortality when OAT is employed, the proportion of people with OUD receiving OAT remains small. One initiative to improve the access and uptake of OAT could be to offer OAT in a primary care setting; primary care clinics are more numerous, might reduce the visibility and potential stigma of receiving treatment for OUD, and may facilitate the care of other medical conditions that are unrelated to OUD.
View Article and Find Full Text PDFBurden of malignant neoplasm of bone and articular cartilage from 1990 to 2021 and its predictions to 2030 in China compared with world.
Front Oncol
August 2025
Department of Orthopaedics, Ruijin Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China.
Objective: To comprehensively examine the incidence and mortality of malignant neoplasms of bone and articular cartilage (MNBAC) in China compared with the world, as well as its age-specific patterns and sex disparities.
Methods: The MNBAC burden in China and the world was systematically assessed from 1990 to 2021 based on the Global Burden of Disease 2021, including incidence and mortality data. The estimated annual percentage change was calculated.
Beyond the First Year of Intravitreal Faricimab for Diabetic Macular Oedema: A Single-Centre Experience.
Cureus
August 2025
Ophthalmology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, GBR.
Objective To determine real-world clinical outcomes (including vision, anatomy and durability) of intravitreal faricimab (IVF) in year two (up to mean follow-up of 75 ± 15 weeks, range: 52-103 weeks) of treating diabetic macular oedema (DMO). Secondary objectives included assessing changes in diabetic retinopathy (DR) severity, the incidence of epiretinal proliferation (ERP)/epiretinal membrane (ERM), and safety. Methodology This is a single-centre retrospective observational study.
View Article and Find Full Text PDF